mepa8 Get alerts

FDA approves oral pimicotinib for adults with symptomatic tenosynovial giant cell tumor

The approval rests on the MANEUVER trial, a double-blind, placebo-controlled study of 50 mg once daily, and the FDA notice lists hepatotoxicity and embryo-fetal toxicity warnings but no efficacy figures.

Mepa8 headline card: FDA approves oral pimicotinib for adults with symptomatic tenosynovial giant cell tumor

Key takeaways

  • On November 10, 2026, the FDA approved pimicotinib, branded Pimjetmi by EMD Serono, for adults with symptomatic tenosynovial giant cell tumor where surgery could cause worsening function or severe morbidity.
  • The approval is based on MANEUVER, a double-blind, placebo-controlled international trial that randomized patients 2:1 to pimicotinib 50 mg or placebo once daily.
  • The most common adverse reactions in the FDA notice are pruritus, rash, face edema, periorbital edema, fatigue, nausea, headache and peripheral edema.
  • The prescribing information carries warnings for hepatotoxicity, embryo-fetal toxicity and increased serum creatinine without a change in renal function.
  • For crews: the FDA notice reports no efficacy numbers, price or launch date, and full prescribing information is still to be posted on Drugs@FDA.

The Food and Drug Administration approved pimicotinib, sold as Pimjetmi by EMD Serono, Inc., on November 10, 2026, for adults with symptomatic tenosynovial giant cell tumor, according to an FDA approval notice posted the same day [1]. The agency classifies the drug as a kinase inhibitor [1].

The approved use is narrow. It covers symptomatic tenosynovial giant cell tumor, or TGCT, "for which surgical resection may cause worsening functional limitation or severe morbidity," the FDA record states [1]. The notice says full prescribing information for Pimjetmi will be posted on Drugs@FDA [1].

The review ran under Project Orbis, a program of the FDA Oncology Center of Excellence that lets several national regulators review an oncology drug at the same time [1]. The record does not say when the drug will be available or what it will cost.

What the records show

Efficacy was evaluated in a trial named MANEUVER, registered as NCT05804045 [1]. The FDA describes it as a double-blind, randomized, placebo-controlled, international study in which patients were assigned 2:1 to drug or placebo [1]. Enrolled patients had a confirmed diagnosis of symptomatic TGCT with measurable disease, and at least one lesion had to measure a minimum of 2 cm [1]. The trial enrolled people for whom surgical removal of the tumor could cause dysfunction or serious complications [1]. Randomization was stratified by geographic region, China versus non-China [1].

Trial patients took pimicotinib 50 mg or placebo once daily [1]. The approved dosage matches the trial: 50 mg by mouth once a day, with or without food [1].

The notice lists the adverse reactions that occurred in more than 20% of patients [1]:

  • pruritus
  • rash
  • face edema
  • periorbital edema
  • fatigue
  • nausea
  • headache
  • peripheral edema

Laboratory abnormalities seen in more than 30% of patients were increases in creatine phosphokinase, lactate dehydrogenase, aspartate aminotransferase, lipase, cholesterol, amylase and alanine aminotransferase [1].

The prescribing information includes warnings and precautions for hepatotoxicity, for embryo-fetal toxicity, and for "increased serum creatinine without affecting renal function," according to the FDA record [1].

For the Project Orbis review, the FDA worked with Australia's Therapeutic Goods Administration, Health Canada, Israel's Ministry of Health, Switzerland's Swissmedic and the United Kingdom's Medicines and Healthcare products Regulatory Agency [1]. The European Medicines Agency took part as an official observer [1]. The FDA notes that applications at the partner agencies may still be in submission or under review [1]. The review also used an Assessment Aid, which the FDA describes as a voluntary submission from the applicant [1]. The record states that pimicotinib "received fast track and breakthrough therapy designation" [1].

Why it matters for clinicians

Patients treated with this drug will be taking a daily oral kinase inhibitor at home, not in a hospital. The adverse reactions the FDA lists include face edema, periorbital edema, peripheral edema, rash and pruritus [1]. Those are findings a patient might report to a primary care office, an emergency department or an ambulance crew, and the record places them among the most frequent effects of the drug [1].

The hepatotoxicity warning sits alongside frequent rises in aspartate aminotransferase and alanine aminotransferase in the trial population [1]. The record also flags that serum creatinine can rise without renal function being affected, a point that bears on how a basic metabolic panel from one of these patients reads [1]. The embryo-fetal toxicity warning applies to patients who are or could become pregnant [1]. The record gives no direction on prehospital or emergency management of adverse effects. EMS clinicians follow local protocols and medical direction.

The FDA asks healthcare professionals to report serious adverse events suspected to be linked to any medicine or device through its MedWatch system or by calling 1-800-FDA-1088 [1]. For help with single-patient investigational new drug requests for oncology products, the notice lists the Oncology Center of Excellence's Project Facilitate at 240-402-0004 or OncProjectFacilitate@fda.hhs.gov [1].

What the records do not tell us

  • No efficacy results. The FDA notice names the trial and its design but reports no response rate, primary endpoint or effect size.
  • No enrollment count. The record does not say how many patients took part in MANEUVER or how long they were treated or followed.
  • No label yet. Full prescribing information is described as forthcoming on Drugs@FDA; the notice does not reproduce it.
  • No price or launch date. The record says nothing about availability, cost or distribution.
  • No company statement. EMD Serono has not commented in the records.
  • No pediatric data. The approval covers adults only, and the record does not discuss use in children.
  • No decisions from partner regulators. The FDA says the applications at the other Project Orbis agencies may still be under review, and no dates are given.

What to watch

The next document is the full Pimjetmi prescribing information, which the FDA says will appear on Drugs@FDA [1]. Decisions from the Australian, Canadian, Israeli, Swiss and UK regulators that joined the Project Orbis review may follow, though the record gives no timeline for any of them [1].

Questions readers ask

What is pimicotinib (Pimjetmi) approved for?

The FDA approved pimicotinib on November 10, 2026, for adults with symptomatic tenosynovial giant cell tumor for which surgical resection may cause worsening functional limitation or severe morbidity. It is marketed as Pimjetmi by EMD Serono, Inc.

What is the recommended dose of pimicotinib?

The FDA record lists the recommended dosage as 50 mg taken orally once daily, with or without food. The same 50 mg daily dose was used in the MANEUVER trial.

What are the most common side effects of pimicotinib?

The FDA notice lists pruritus, rash, face edema, periorbital edema, fatigue, nausea, headache and peripheral edema as adverse reactions in more than 20% of patients. The prescribing information also carries warnings for hepatotoxicity, embryo-fetal toxicity and increased serum creatinine without affecting renal function.

What trial supported the FDA approval of pimicotinib?

Efficacy was evaluated in MANEUVER (NCT05804045), a double-blind, randomized 2:1, placebo-controlled international trial in patients with symptomatic TGCT and at least one lesion of 2 cm or larger. The FDA notice does not report the trial's efficacy results or enrollment number.

Sources

  1. FDA: FDA approves pimicotinib for symptomatic tenosynovial giant cell tumor (November 10, 2026) — fda.gov (2026-11-10). fda.gov/drugs/cancer-approvals/fda-approves-pimicotinib-symptomatic-te
How this story was made Drafted by Mepa8's AI newsroom from the 1 record listed above and nothing else. Before publication a verification program confirmed that every number and quotation in the story appears in those records, that no passage was copied from them, and that every cited link opens. Editor: Ryan Bolden, EMS professional, who reviews published stories and handles corrections. Medical review pending. How we use AI · Report an error

This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.

Free alerts

Know about the next recall or outbreak the day it is posted.

One email when a story touches EMS equipment, medications or public health. Plus the free 6am briefing if you want it.

Send me